Results 181 to 190 of about 232,812 (303)
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network (EMN) Italy
British Journal of Haematology, EarlyView.Summary
The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT) Gregorio Barilà, Angela Grassi, Valeria Ruocco, Carmine Liberatore, Edoardo Olivari, Martina Tinelli, Francesca Fazio, Sonia Morè, Emanuele Favero, Claudio Salvatore Cartia, Nicola Sgherza, Concetta Conticello, Roberto Mina, Martina Gherardini, Giuseppe Mele, Massimo Gentile, Anna Furlan, Massimiliano Arangio Febbo, Maria Livia Del Giudice, Ombretta Annibali, Bernardo Rossini, Edoardo Scomazzon, Marco Talarico, Enrica Antonia Martino, Claudio De Magistris, Francesca Fioritoni, Anna Maria Cafro, Laura Paris, Sara Pezzatti, Roberta Della Pepa, Paola Boggione, Giuseppe Pietrantuono, Valeria Tomarchio, Francesco Vassallo, Maria Luisa Pioltelli, Francesco Pisani, Antonia Cagnetta, Lorenzo De Paoli, Gabriele Buda, Elisabetta Antonioli, Monica Galli, Alberto Tosetto, Pellegrino Musto, Elena Zamagni, Francesca Patriarca, Silvia Mangiacavalli, Renato Zambello, Massimo Offidani, Maria Teresa Petrucci +48 morewiley +1 more sourceIntegrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma. [PDF]
Cancer ResCanevarolo RR, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, DeAvila D, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst L, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer J, Dalton W, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. +34 moreeuropepmc +1 more sourcePrognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
Blood Cancer JournalMansi R. Shah, Aishee Bag, Asis Shrestha, Yetunde Ogunsesan, Anup Trikannad, Sruthi Vellanki, Sanjay Muttineni, Hira Cheema, Syed Naqvi, Sasya Dronavalli, Samer Al Hadidi, Sharmilan Thanendrarjan, Maurizio Zangari, Frits van Rhee, Aniko Szabo, Rajshekar Chakraborty, Meera Mohan, Carolina Schinke +17 moredoaj +1 more sourceSecond Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study. [PDF]
Clin Cancer ResSuvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K. +13 moreeuropepmc +1 more sourceReal‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria
British Journal of Haematology, EarlyView.Summary
B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler‐Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer‐Ausch, Sigrid Machherndl‐Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Werner Rabitsch, Axel Schulenburg, Hermine Agis, Maria‐Theresa Krauth +23 morewiley +1 more sourceEnhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers. [PDF]
Nat CommunPonnusamy K, Karaxhuku K, Jiang Y, Randzavola L, Ren H, Leontari I, Lye B, Zaidi M, Bartlett EJ, Tate EW, Pardalis V, Leonardos D, Nadafi R, Sarkar I, Reijmers RM, Bua M, Atta M, Katsarou A, Roberts IA, Chaidos A, Karadimitris A. +20 moreeuropepmc +1 more sourceReal-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. [PDF]
World J Exp MedBangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. +38 moreeuropepmc +1 more sourceDevelopment and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests
British Journal of Haematology, EarlyView.Summary
Haematological malignancies are rare in primary care and are hard to predict. Existing prediction models often require a specific working diagnosis and are based on extensive clinical information, access to which may be limited at initial work‐up in primary care.Mathilde Egelund Christensen, Michael Charles Sachs, William Grant Dunn, Gustav Jonzon, Margit Kriegbaum, Bent Struer Lind, Jan Samuelsson, Kirsten Groenbaek, George Vassiliou, Christen Lykkegaard Andersen +9 morewiley +1 more source
